PL1666496T3 - Kompozyt interferonu beta - Google Patents

Kompozyt interferonu beta

Info

Publication number
PL1666496T3
PL1666496T3 PL04772408T PL04772408T PL1666496T3 PL 1666496 T3 PL1666496 T3 PL 1666496T3 PL 04772408 T PL04772408 T PL 04772408T PL 04772408 T PL04772408 T PL 04772408T PL 1666496 T3 PL1666496 T3 PL 1666496T3
Authority
PL
Poland
Prior art keywords
interferon
beta composite
beta
composite
Prior art date
Application number
PL04772408T
Other languages
English (en)
Inventor
Hideki Narumi
Yoshiaki Tsushima
Koji Yamashita
Saburou Sone
Miyuki Sato
Tadatsugu Taniguchi
Original Assignee
Toray Industries
Tadatsugu Taniguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Tadatsugu Taniguchi filed Critical Toray Industries
Publication of PL1666496T3 publication Critical patent/PL1666496T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL04772408T 2003-08-25 2004-08-24 Kompozyt interferonu beta PL1666496T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003299850 2003-08-25
EP04772408.3A EP1666496B1 (en) 2003-08-25 2004-08-24 Interferon-beta composite
PCT/JP2004/012452 WO2005019260A1 (ja) 2003-08-25 2004-08-24 インターフェロンβ複合体

Publications (1)

Publication Number Publication Date
PL1666496T3 true PL1666496T3 (pl) 2014-08-29

Family

ID=34213782

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04772408T PL1666496T3 (pl) 2003-08-25 2004-08-24 Kompozyt interferonu beta

Country Status (11)

Country Link
US (2) US7691975B2 (pl)
EP (1) EP1666496B1 (pl)
JP (1) JP4850514B2 (pl)
KR (1) KR101157679B1 (pl)
CN (2) CN100519581C (pl)
AU (1) AU2004266969B2 (pl)
CA (1) CA2536643C (pl)
ES (1) ES2452640T3 (pl)
PL (1) PL1666496T3 (pl)
PT (1) PT1666496E (pl)
WO (1) WO2005019260A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116948A1 (en) * 2005-04-30 2006-11-09 Chengdu Institute Of Biological Products Interleukin-6 polyethylene glycol conjugate and its preparing method and use
ES2387236T3 (es) 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
GB0912485D0 (en) 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
KR101979045B1 (ko) 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물
US20150030564A1 (en) * 2012-02-29 2015-01-29 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
JP2017100946A (ja) * 2014-03-28 2017-06-08 東レ株式会社 悪液質の治療剤又は予防剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6372207B1 (en) * 1997-12-19 2002-04-16 Applied Research Systems Ars Holding N.V. IFNAR2/IFN complex
HU229888B1 (en) * 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
CA2382066C (en) * 1999-08-20 2006-11-21 Honeybaked Ham, Inc. Apparatus for coating meat
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
SK2942002A3 (en) * 1999-08-27 2002-08-06 Maxygen Aps A conjugate exhibiting interferon beta, a nucleotide sequence, an expressing vector, a host cell containing such a nucleotide sequence, method for the preparation thereof, pharmaceutical composition containing the same and its use
AU2223401A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Branched polyalkylene glycols
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
JP2004035515A (ja) * 2002-07-05 2004-02-05 Toray Ind Inc インターフェロンβ複合体の製造方法

Also Published As

Publication number Publication date
EP1666496A1 (en) 2006-06-07
US20100145017A1 (en) 2010-06-10
KR20060134905A (ko) 2006-12-28
AU2004266969B2 (en) 2010-02-25
CN101880326B (zh) 2018-02-16
AU2004266969A1 (en) 2005-03-03
CN100519581C (zh) 2009-07-29
CN101880326A (zh) 2010-11-10
KR101157679B1 (ko) 2012-06-20
CN1871257A (zh) 2006-11-29
US20060246034A1 (en) 2006-11-02
ES2452640T3 (es) 2014-04-02
JPWO2005019260A1 (ja) 2007-11-01
US7915386B2 (en) 2011-03-29
EP1666496B1 (en) 2014-03-12
PT1666496E (pt) 2014-06-24
WO2005019260A1 (ja) 2005-03-03
CA2536643A1 (en) 2005-03-03
JP4850514B2 (ja) 2012-01-11
EP1666496A4 (en) 2006-09-13
US7691975B2 (en) 2010-04-06
CA2536643C (en) 2013-11-12

Similar Documents

Publication Publication Date Title
GB2409458B (en) Composite materials
GB2386836B (en) Anti-cancer combinations
GB0322140D0 (en) Combinations
PL371113A1 (pl) Profil zespolony
GB0307975D0 (en) Composite structure
HU0900090V0 (en) Brick composite
GB0324483D0 (en) Composite material
GB0321699D0 (en) Fibre-plastics composite
GB2421742B (en) Structural arrangement
PL1666496T3 (pl) Kompozyt interferonu beta
GB0220510D0 (en) Composite board
GB0510737D0 (en) Rigid composite structure
EP1701926A4 (en) ORGANIC-INORGANIC COMPOSITE
GB0208304D0 (en) Composite structures
GB0315042D0 (en) Composite material
GB2449782B (en) Composite materials
GB0401752D0 (en) Cabin
GB0306072D0 (en) Laminate
GB0318333D0 (en) Laminate
GB0313210D0 (en) Composite structure
GB0222115D0 (en) Improved composite structures
GB0321391D0 (en) Flexi-facial plus
TW566336U (en) Honeycomb-paper-core type composite sheet
GB0329865D0 (en) Composite rail
GB0325288D0 (en) Composite structural component improvements